Olmesartan Medoxomil/Hydrochlorothiazide Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Hydrochlorothiazide Krka, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what an ARB alone can provide.

GNH USA supplies Olmesartan Medoxomil/Hydrochlorothiazide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to lower elevated blood pressure. - Hypertension: provides additional blood pressure reduction when monotherapy is insufficient. - Hypertensive patients with fluid retention: combines an ARB with a thiazide diuretic to improve volume control. - High‑risk cardiovascular patients: helps achieve guideline‑recommended blood pressure targets to lower cardiovascular event risk.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Severe electrolyte imbalance (e.g., hyponatremia) - Pancreatitis

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - Volume status: watch for dehydration, especially in the elderly. - Concomitant drugs: avoid use with other potent diuretics or potassium‑sparing agents without monitoring. - Pregnancy: contraindicated in the second and third trimesters; assess risk‑benefit in the first trimester. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Olmesartan Medoxil/Hydrochlorothiazide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): may increase risk of renal dysfunction and hyperkalemia. - Lithium: concurrent use can raise lithium levels, risking toxicity. - NSAIDs (high‑dose or chronic): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Antidiabetic agents: may enhance hypoglycaemic effect. - Antimicrobials such as trimethoprim‑sulfamethoxazole: can increase serum potassium.